Last reviewed · How we verify
Surufatinib in combination with Gemcitabine
Surufatinib in combination with Gemcitabine is a Small molecule drug developed by Hutchmed. It is currently in Phase 1 development. Also known as: HMPL-012, sulfatinib in combination with Gemcitabine.
At a glance
| Generic name | Surufatinib in combination with Gemcitabine |
|---|---|
| Also known as | HMPL-012, sulfatinib in combination with Gemcitabine |
| Sponsor | Hutchmed |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer (PHASE3)
- Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer (PHASE2)
- A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PHASE2, PHASE3)
- Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer (PHASE2)
- A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer (PHASE2)
- Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer (PHASE1, PHASE2)
- Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer (PHASE2)
- Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Surufatinib in combination with Gemcitabine CI brief — competitive landscape report
- Surufatinib in combination with Gemcitabine updates RSS · CI watch RSS
- Hutchmed portfolio CI
Frequently asked questions about Surufatinib in combination with Gemcitabine
What is Surufatinib in combination with Gemcitabine?
Surufatinib in combination with Gemcitabine is a Small molecule drug developed by Hutchmed.
Who makes Surufatinib in combination with Gemcitabine?
Surufatinib in combination with Gemcitabine is developed by Hutchmed (see full Hutchmed pipeline at /company/hutchmed).
Is Surufatinib in combination with Gemcitabine also known as anything else?
Surufatinib in combination with Gemcitabine is also known as HMPL-012, sulfatinib in combination with Gemcitabine.
What development phase is Surufatinib in combination with Gemcitabine in?
Surufatinib in combination with Gemcitabine is in Phase 1.
Related
- Manufacturer: Hutchmed — full pipeline
- Also known as: HMPL-012, sulfatinib in combination with Gemcitabine
- Compare: Surufatinib in combination with Gemcitabine vs similar drugs
- Pricing: Surufatinib in combination with Gemcitabine cost, discount & access